BioSyent (CVE:RX) Share Price Passes Above Fifty Day Moving Average – What’s Next?

BioSyent Inc. (CVE:RX) passed above its 50-day moving average during trading on Thursday . The stock has a 50-day moving average of C$11.35 and traded as high as C$11.43. BioSyent shares last traded at C$11.43, with a volume of 100 shares trading hands.

BioSyent Stock Up 1.5 %

The business’s fifty day moving average is C$11.35 and its two-hundred day moving average is C$10.80. The stock has a market cap of C$132.47 million, a price-to-earnings ratio of 19.05 and a beta of 0.93. The company has a quick ratio of 6.91, a current ratio of 6.13 and a debt-to-equity ratio of 3.19.

Insiders Place Their Bets

In related news, insider FAX Capital Corp. sold 112,400 shares of the company’s stock in a transaction that occurred on Monday, December 23rd. The shares were sold at an average price of C$11.28, for a total transaction of C$1,267,557.28. Also, Senior Officer Robert Joseph March sold 4,775 shares of the firm’s stock in a transaction that occurred on Thursday, December 12th. The shares were sold at an average price of C$11.65, for a total transaction of C$55,628.75. Insiders sold a total of 349,144 shares of company stock worth $3,903,370 over the last 90 days. Corporate insiders own 33.65% of the company’s stock.

BioSyent Company Profile

BioSyent Inc, together with its subsidiaries, acquires or licenses, develops, and sells pharmaceutical and other healthcare products in Canada and internationally. Its products include FeraMAX Pd Therapeutic 150 for the treatment of iron deficiency anemia; FeraMAX Pd Maintenance 45, a chewable supplement for the prevention of iron deficiency anemia; and FeraMAX Pd Powder 15, a powder form product used for preventing iron deficiency and iron deficiency anemia.